1. Home
  2. CPHI vs VIVS Comparison

CPHI vs VIVS Comparison

Compare CPHI & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

HOLD

Current Price

$1.31

Market Cap

6.8M

Sector

Health Care

ML Signal

HOLD

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$2.08

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPHI
VIVS
Founded
N/A
2007
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8M
8.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CPHI
VIVS
Price
$1.31
$2.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
52.8K
35.7K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,052,266.00
$140,000.00
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.92
52 Week Low
$1.20
$1.41
52 Week High
$3.35
$21.96

Technical Indicators

Market Signals
Indicator
CPHI
VIVS
Relative Strength Index (RSI) 33.94 46.35
Support Level $1.30 $1.82
Resistance Level $1.49 $2.05
Average True Range (ATR) 0.13 0.16
MACD -0.03 -0.01
Stochastic Oscillator 1.72 37.95

Price Performance

Historical Comparison
CPHI
VIVS

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: